{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:05:32Z","timestamp":1761743132676,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.3816\/cbc.2002.n.030","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:04:58Z","timestamp":1221080698000},"page":"268-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Phase III Trial Comparing Granulocyte Colony-Stimulating Factor to Leridistim in the Prevention of Neutropenic Complications in Breast Cancer Patients Treated with Docetaxel\/Doxorubicin\/Cyclophosphamide: Results of the BCIRG 004 Trial"],"prefix":"10.3816","volume":"3","author":[{"given":"Jean-Marc","family":"Nabholtz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Cantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Guevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Tkaczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Vodvarka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Ann","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2002.n.030_bib1","first-page":"127a","article-title":"A phase III trial comparing doxorubicin and docetaxel (AT) to doxorubicin and cyclophosphamide (AC) as first line therapy for MBC","volume":"18","author":"Nabholtz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib2","first-page":"22a","article-title":"A phase III randomized trial comparing docetaxel (T), doxorubicin (A), and cyclophosphamide (C) (TAC) to FAC as first-line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)","volume":"20","author":"Nabholtz","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib3","first-page":"1583","article-title":"2000 update of recommendations for the use of hemotopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","volume":"19","author":"Ozer","year":"2001","journal-title":"American Society of Clinical Oncology Growth Factors Expert Panel"},{"key":"10.3816\/CBC.2002.n.030_bib4","first-page":"552","article-title":"Hematopoietic growth factors in the reduction of chemotherapeutic toxicity","volume":"25","author":"Johnston","year":"1998","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib5","first-page":"332","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","author":"Group","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2002.n.030_bib6","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","article-title":"Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"13","author":"Chevallier","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00001813-199506000-00002","article-title":"Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience","volume":"6","author":"van Oosterom","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CBC.2002.n.030_bib9","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib12","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2000.18.12.2369","article-title":"Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196","volume":"18","author":"Sparano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib14","first-page":"174b","article-title":"Myelopoietin: biochemical mechanism of action studies","volume":"92","author":"Monahan","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CBC.2002.n.030_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0301-472X(01)00611-7","article-title":"Bivalent binding and signaling characteristics of leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptors","volume":"29","author":"Monahan","year":"2001","journal-title":"Exp Hematol"},{"key":"10.3816\/CBC.2002.n.030_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood.V95.3.837.003k08_837_845","article-title":"Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression","volume":"95","author":"MacVittie","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CBC.2002.n.030_bib17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0301-472X(99)00092-2","article-title":"Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates","volume":"27","author":"MacVittie","year":"1999","journal-title":"Exp Hematol"},{"issue":"suppl 1","key":"10.3816\/CBC.2002.n.030_bib18","first-page":"173a","article-title":"Phase I\/II study to determine the safety and tolerability of SC-70935 in patients with relapsed lymphoma receiving ESHAP","volume":"90","author":"Abboud","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CBC.2002.n.030_bib19","first-page":"6a","article-title":"A phase I\/II study of SC-70935, a novel hematopoietic growth factor with dual receptor against activity, demonstrates enhanced neutrophil recovery in advanced breast cancer patients receiving docetaxel","volume":"17","author":"Hamm","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2002.n.030_bib20","first-page":"43","article-title":"Interpretation of statistical methodology associated with maintenance trials","volume":"77","author":"Koch","year":"1984","journal-title":"Am J Med"},{"key":"10.3816\/CBC.2002.n.030_bib21","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2307\/2533489","article-title":"Mantel-Haenszel test statistics for correlated binary data","volume":"53","author":"Zhang","year":"1997","journal-title":"Biometrics"},{"key":"10.3816\/CBC.2002.n.030_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2002.n.030_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.3816\/CBC.2002.n.030_bib24","first-page":"5155","article-title":"Human hematopoietic growth factors: old lessons and new perspectives","volume":"20","author":"Dempke","year":"2000","journal-title":"Anticancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911702543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911702543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:07:00Z","timestamp":1761512820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911702543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S1526820911702543"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2002.n.030","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2002,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase III Trial Comparing Granulocyte Colony-Stimulating Factor to Leridistim in the Prevention of Neutropenic Complications in Breast Cancer Patients Treated with Docetaxel\/Doxorubicin\/Cyclophosphamide: Results of the BCIRG 004 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2002.n.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}